Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
An. bras. dermatol ; 95(3): 271-277, May-June 2020. tab
Article Dans Anglais | LILACS, ColecionaSUS | ID: biblio-1130879

Résumé

Abstract Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.


Sujets)
Humains , Mâle , Troubles sexuels d'origine physiologique/induit chimiquement , Finastéride/effets indésirables , Inhibiteurs de la 5-alpha réductase/effets indésirables , Spermatozoïdes/effets des médicaments et des substances chimiques , Syndrome , Maladies cardiovasculaires/induit chimiquement , Facteurs de risque , Infertilité/induit chimiquement , Troubles mentaux/induit chimiquement , Maladies métaboliques/induit chimiquement
SÉLECTION CITATIONS
Détails de la recherche